Analysts predict that Antares Pharma, Inc. (NASDAQ:ATRS) will post $0.03 earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.05. Antares Pharma also posted earnings per share of $0.03 in the same quarter last year. The company is scheduled to issue its next quarterly earnings results on Tuesday, March 2nd.
According to Zacks, analysts expect that Antares Pharma will report full-year earnings of $0.06 per share for the current financial year, with EPS estimates ranging from $0.04 to $0.09. For the next fiscal year, analysts forecast that the business will report earnings of $0.25 per share, with EPS estimates ranging from $0.13 to $0.39. Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, November 10th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $36.09 million.
A number of equities research analysts recently issued reports on the company. Raymond James reaffirmed a “buy” rating on shares of Antares Pharma in a research note on Thursday, October 1st. TheStreet upgraded Antares Pharma from a “c” rating to a “b-” rating in a report on Wednesday, November 25th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Thursday, December 17th. Finally, Zacks Investment Research downgraded Antares Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, October 12th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $5.15.
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon “Unstoppable.” This under-the-radar company is not yet a household name.
In other news, CFO Fred M. Powell acquired 16,400 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was acquired at an average cost of $2.85 per share, for a total transaction of $46,740.00. Following the acquisition, the chief financial officer now directly owns 646,465 shares in the company, valued at approximately $1,842,425.25. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 5.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Antares Pharma by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 8,069,904 shares of the specialty pharmaceutical company’s stock worth $22,192,000 after buying an additional 167,927 shares during the last quarter. FMR LLC increased its holdings in shares of Antares Pharma by 46.6% during the 2nd quarter. FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. Silvercrest Asset Management Group LLC increased its holdings in shares of Antares Pharma by 21.5% during the 2nd quarter. Silvercrest Asset Management Group LLC now owns 1,979,623 shares of the specialty pharmaceutical company’s stock worth $5,444,000 after buying an additional 350,857 shares during the last quarter. Oracle Investment Management Inc. increased its holdings in shares of Antares Pharma by 38.5% during the 2nd quarter. Oracle Investment Management Inc. now owns 1,699,566 shares of the specialty pharmaceutical company’s stock worth $4,674,000 after buying an additional 472,452 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Antares Pharma by 5.5% in the 2nd quarter. Two Sigma Advisers LP now owns 1,653,532 shares of the specialty pharmaceutical company’s stock valued at $4,547,000 after purchasing an additional 86,700 shares in the last quarter. Institutional investors and hedge funds own 38.96% of the company’s stock.
ATRS stock opened at $3.99 on Friday. Antares Pharma has a 1 year low of $1.60 and a 1 year high of $4.73. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.08 and a current ratio of 2.47. The stock’s 50 day moving average price is $3.37 and its 200 day moving average price is $2.97. The firm has a market cap of $665.02 million, a P/E ratio of 66.51 and a beta of 1.41.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: How to interpret the current ratio
Get a free copy of the Zacks research report on Antares Pharma (ATRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Retail Stocks to Own For the Long Haul
There are more than 500 national retailers traded on the NYSE and the NASDAQ. Given the sheer number of big box stores, warehouse clubs, restaurant chains, and other retail stores listed on public markets, it can be hard to identify which retailers will outperform the market.
Fortunately, some of Wall Street’s top analysts have already done most of the work for us.
Every year, analysts issue approximately 4,200 distinct recommendations for retail companies. Analysts may not always get their “buy” ratings right, but it’s worth taking a hard look when several analysts from different brokerages and research firms are giving “strong-buy” and “buy” ratings to the same retailer.
This slide show lists the 8 retail companies with the highest average analyst recommendations from Wall Street’s equities research analysts over the last 12 months.
